Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Key facts
- Where
- Albuquerque, Auburn Hills, Baltimore, Bellaire, Birmingham, Boston, Bowling Green, Dallas, Danville, Detroit, El Paso, Farmington, Gambrills, Kansas City, Leawood, Miami, Missoula, Phoenix, Sandy Springs, Skokie, South Jordan, St Louis, Tampa, and Troy, United StatesSee the 26 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 17 years old?
Source: NCT07213973, who can take part
Where in United States
- University of New Mexico HospitalAlbuquerque, United StatesTaking people
- Oakland Hills Dermatology PCAuburn Hills, United StatesTaking people
- Johns Hopkins Univ Schl of MedicineBaltimore, United StatesTaking people
- Bellaire Dermatology Associates BdaBellaire, United StatesTaking people
- University of Alabama at BirminghamBirmingham, United StatesTaking people
- Boston Childrens HospitalBoston, United StatesTaking people
- Equity MedicalBowling Green, United StatesTaking people
- Texas Dermatology Research CenterDallas, United StatesTaking people
- Geisinger Medical CenterDanville, United StatesTaking people
- Wayne State University Physician Group DermatologyDetroit, United StatesTaking people
- 3A Research Llc West LocationEl Paso, United StatesTaking people
- UConn HealthFarmington, United StatesTaking people
- Skin Oasis DermatologyGambrills, United StatesNot yet recruiting
- University of Missouri-Kansas CityKansas City, United StatesNot yet recruiting
- Dermatology Skin Cancer Center LeawoodLeawood, United StatesTaking people
- Skin Research of South Florida, LlcMiami, United StatesTaking people
- University of Miami Miller School of MedicineMiami, United StatesTaking people
- Boeson Research Missoula 2825 Fort Missoula RdMissoula, United StatesTaking people
- Medical Dermatology Specialists PhoenixPhoenix, United StatesTaking people
- Saguaro DermatologyPhoenix, United StatesTaking people
- Advanced Medical Research, PC.Sandy Springs, United StatesTaking people
- Endeavor Health Medical GroupSkokie, United StatesTaking people
- Jordan Valley Dermatology CenterSouth Jordan, United StatesTaking people
- Washington UniversitySt Louis, United StatesTaking people
- TrueBlue Clinical ResearchTampa, United StatesTaking people
- Revival Research Institute, Llc TroyTroy, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Incyte Corporation
- Trial code
- NCT07213973
- Record updated
- 9 October 2026
- Original description
The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.Read full original descriptionShow less
A Phase 2, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Povorcitinib in Adolescents With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.
Inclusion: Aged ≥ 12 to < 18 years at the time of informed consent/assent signing; Body weight ≥ 30 kg at both screening and baseline visits; Diagnosis of moderate to severe HS for at least 3 months prior to the screening visit; Total abscess and inflammatory nodule count of at least 5 at both the screening and baseline visits; HS lesions corresponding to refined Hurley Stage IB, IC, IIB, IIC, or III at both the screening and baseline visits; Documented history of inadequate response to at least a 3-month course of at least 1 conventional systemic therapy (oral antibiotic or biologic drug) for HS (or demonstrated intolerance to, or have a contraindication to, a conventional systemic therapy for treatment of their HS); Agreement to use contraception; Willing and able to comply with the study protocol and procedures; Further inclusion criteria apply.
Exclusion: Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q-wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator; Laboratory values outside of the protocol-defined ranges; Presence of > 20 draining tunnels (fistulas) at either the screening or baseline visit; Women who are pregnant (or who are considering pregnancy) or breastfeeding; Further exclusion criteria apply.